Moreover, inhibition by ATO was more pronounced in prostate cancer cells expressing androgen receptor than in prostate cancer cells depleted of androgen receptor, and inhibition of androgen receptor activity by ATO and by the androgen receptor antagonist, bicalutamide, was additive [24]. The gene discussed is AR; the disease is prostate cancer.